|March 13, 2014|
|09:21 EDT||AMZN, HZNP, WSM, PLUG, EA, MEI, KKD, DG, ATVI, Q, APPY, CALL||On The Fly: Pre-market Movers |
UP AFTER EARNINGS: Plug Power (PLUG), up 11%... Krispy Kreme (KKD), up 8%... Williams-Sonoma (WSM), up 6.8%... magicJack (CALL), up 22%. ALSO HIGHER: Amazon.com (AMZN), up 1.9% after raising price on Prime membership for existing members to $99... Venaxis (APPY), up 20% after APPY1 test shows positive top-line results... Activision Blizzard (ATVI), up 4% following upgrade at BofA Merrill Lynch. DOWN AFTER EARNINGS: Dollar General (DG), down 1.7%... Methode Electronics (MEI), down 11%... Horizon Pharma (HZNP), down 2.4%. ALSO LOWER: Quintiles (Q), down 2% after 15M share Secondary priced at $52.00... Electronic Arts (EA), down 1.8% following downgrade at BofA Merrill Lynch.
News For AMZN;ATVI;EA;CALL;DG;PLUG;APPY;KKD;WSM;Q;MEI;HZNP From The Last 14 Days
|September 23, 2015|
|10:24 EDT||AMZN||Options with increasing implied volatility|
Options with increasing implied volatility: SNCR PTCT SRPT AMZN CREE CMG ISRG QLIK SNKD BIIB JNPR
|09:18 EDT||AMZN||Paulson Institute and CCPIT to co-host U.S.-China Business Roundtable|
The Paulson Institute and the China Council for the Promotion of International Trade (CCPIT) provide an opportunity for U.S. and Chinese business leaders to discuss issues facing the two countries in a roundtable being held in Seattle, Washington on September 23.
|08:34 EDT||HZNP||Argos names Robert Carey to board of directors|
Subscribe for More Information
|07:40 EDT||HZNP||Horizon Pharma weakness creates buying opportunity, says Stifel|
Stifel believes that Horizon Pharma's stock has been pressured in recent days due to worries about prescription trends and statements about drug pricing. However, the firm thinks that the company is on track to beat Q3 revenue expectations and its 2015 revenue guidance. It does not expect the "rhetoric" about drug pricing to impact the company and it keeps a $45 price target and Buy rating on the shares.
|05:56 EDT||EA||Reviews solid for EA's FIFA 16, says Piper Jaffray|
Subscribe for More Information
|September 22, 2015|
|20:02 EDT||HZNP||Clinton vows $250 cap on monthly drug costs in blast against biotechs, insurers|
Democratic presidential candidate Hillary Clinton railed against biotech companies as well as health insurers at a community health care forum in Iowa on Tuesday. Clinton began her speech by praising the Affordable Care Act, but quickly noted that she wants to strengthen it due to what she called the rising cost of prescription drugs. She explained, "Our pharmaceutical and biotechnology industries deserve credit... [But] too often, these drugs cost a fortune. Now, sometimes there is a good reason for that. Scientific breakthroughs are often the result of major investment... so it may makes sense, for a short period of time, to have to charge a lot of money for a drug. But when a drug has no competition, when there aren't any other treatments that can do what it does, pharmaceutical companies can charge astronomical fees far beyond anything that it would take to recoup their investment, and far beyond what they charge consumers anywhere else in the world outside of America." Referencing the recent criticism against Turing Pharmaceuticals, Clinton went on to say that "pharmaceutical companies that acquire an existing affordable drug that people rely on, and then turn around and charge a fortune for it, [are just betting] on the fact that desperate people will find some way to pay for it." Preemptively responding to questions of whether greater regulation will dampen investment, Clinton commented that "some people worry that my proposals will threaten innovation, but I have designed a plan that will do exactly the opposite... Under my plan, drug companies that want to keep getting federal support will have to redirect more of their profits into meaningful investments in research and development." Clinton also criticized incremental drug improvements, saying that "too often, so-called new drugs are really old drugs that have just been tweaked a little bit, but then they're marketed as breakthrough drugs and they're sold for high prices." The Democratic candidate went on to condemn advertising in the drug industry, remarking that "I also want to tackle direct to consumer advertising... Other countries ban these ads because they are so often misleading. But at the very least, we shouldn't be encouraging them with corporate write-offs... Under my plan, we will instead use that taxpayer money to fund innovation... I would also like to make sure any ads the drug industry does run are approved by the FDA." Moving more broadly onto Medicaid and health insurers, Clinton stated, "I believe Medicare should be able to negotiate for lower prices for its members... I will require drug companies to provide higher rebates for prescription drugs to low income Medicare patients, just like they have to do for Medicaid patients... I think the insurance companies need to be put on notice." Providing more concrete details of her plan, Clinton concluded, "I will cap out of pocket drug costs for working families. You won't have to pay more than $250 a month for covered medications... Particularly for people who have a chronic illness. Also under my plan, you will be able to import cheaper drugs from other countries legally. If the medicine you need costs less in Canada, you should be able to buy it from Canada or any other country that meets our safety standards... I will also make sure we have more generics on the market [by boosting funding for] the FDA's office of generic drugs."
|17:35 EDT||HZNP||Hillary Clinton vows to cap out-of-pocket drug costs at $250 per month|
Presidential candidate Hillary Clinton said in a tweet that, "Under my plan, I'll cap out-of-pocket drug costs for families. You won't have to pay more than $250/month for covered medications." Reference Link
|14:45 EDT||HZNP||Diplomat Pharmacy addresses unusual market activity |
Diplomat Pharmacy (DPLO) is aware of unusual market activity in its stock, potentially in respect to a deal in which Diplomat was incorrectly referenced. Diplomat is aware of a recent development regarding Depomed (DEPO) and Horizon Pharma (HZNP), in which it is not involved. Diplomat heard from an investor that the Diplomat name was incorrectly referenced instead of Depomed, in a discussion between that investor and a bank earlier. We reference such statement only to explain the potential market confusion and we are not commenting on the validity of the statement in any respect. Diplomat has noted that in terms of both shares traded and stock price decline thus far Tuesday, its stock is unusually correlated to Depomed and Horizon Pharma.
|10:23 EDT||AMZN||Options with increasing implied volatility|
Subscribe for More Information
|10:07 EDT||AMZN||Media companies adjust Netflix strategy ahead of OTT growth, Bloomberg says|
Subscribe for More Information
|10:02 EDT||PLUG||Plug Power management to meet with Craig Hallum|
Subscribe for More Information
|10:01 EDT||HZNP||On The Fly: Analyst Downgrade Summary|
Today's noteworthy downgrades include: ABB (ABB) downgraded to Underweight from Neutral at JPMorgan... Aaron's (AAN) downgraded to Market Perform from Outperform at Raymond James... Allison Transmission (ALSN) downgraded to Hold from Buy at Deutsche Bank... Anglo American (AAUKY) downgraded to Neutral from Outperform at Credit Suisse... Antofagasta (ANFGY) downgraded to Underperform from Neutral at Credit Suisse... Atmel (ATML) downgraded to Hold from Buy at Needham... Cummins (CMI) downgraded to Hold from Buy at Deutsche Bank... DuPont Fabros (DFT) downgraded to Sector Perform at RBC Capital... F5 Networks (FFIV) downgraded to Neutral from Buy at Guggenheim... Horizon Pharma (HZNP) downgraded to Hold from Buy at Brean Capital... Infoblox (BLOX) downgraded to Hold from Buy at Deutsche Bank... Israel Chemicals (ICL) downgraded to Sell from Neutral at Goldman... NetApp (NTAP) downgraded to Sell from Neutral at Goldman... Nimble Storage (NMBL) downgraded to Neutral from Buy at Goldman... Oxford Instruments (OXINF) downgraded to Underperform from Hold at Jefferies... Societe Generale (SCGLY) downgraded to Neutral from Overweight at JPMorgan... Toronto-Dominion (TD) downgraded to Neutral from Outperform at Credit Suisse... Virgin America (VA) downgraded to Market Perform from Outperform at Raymond James.
|09:04 EDT||WSM||PBteen announces product collaboration with YouTube|
Subscribe for More Information
|08:23 EDT||HZNP||Analysts say buy select biotech stocks ahead of Clinton drug plan|
Ahead of Presidential candidate Hillary Clinton laying out her plan to tackle "price gouging" in the specialty drug market at an event in Iowa later today, analysts at research firms Jefferies and Piper Jaffray are recommending select biotech stocks that they view as buys amid the weakness in the space. DEBATE: Biotech stocks broadly declined yesterday, with the NASDAQ Biotechnology index (IBB) sliding roughly 4.4%, after privately-held Turing Pharmaceuticals made headlines by enacting a 5,000% price increase on a 62-year-old drug that fights complication of AIDS and cancer. Furor around the sudden price hike for Turing's Daraprim reignited a debate around drug prices that previously embroiled costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni. The news also follows Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Pfizer's (PFE) Hospira, in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. Presidential candidate Hillary Clinton sent the debate to center stage yesterday by criticizing the "outrageous" prices of specialty drugs and promising to lay out a plan today to tackle "price gouging" in the specialty drug market. Clinton's proposal, which she'll outline in a speech in Iowa later today, would force pharmaceutical companies to reinvest their profits into research, allow for more generic and imported drugs and allow Medicare to negotiate lower drug costs and cap out-of-pocket expenses, according to details of the plan shared with USA Today. Zeke Emanuel, chair of medical ethics and health policy at the University of Pennsylvania, appeared on Nightly Business Report to discuss the problem of high drug prices and his suggested solutions. During his interview, Emanuel contended that giving Medicare the ability to negotiate drug prices may drive up prices for everyone else. DEFENSES: The Jefferies Biotechnology research team, led by Brian Abrahams, Eun Yang and Biren Amin, say their Washington D.C. consultants indicate the recent political rhetoric around drug pricing is unlikely to result in any substantive future policy changes that would impact biotech sector fundamentals. As such, they recommend using yesterday's selloff to buy select companies including Celgene (CELG), BioMarin (BMRN) and Alkermes (ALKS). Pricing concerns are nothing new, and will likely continue to be a headwind for the sector, the analysts tell investors in a research note. Hillary Clinton's proposal to combat drug pricing is likely to include "some combination of old and tried policies that have been out there for a few years," they write. The analysts also like shares of AMAG Pharmaceuticals (AMAG), Alder Biopharmaceuticals (ALDR) and Cempra (CEMP). Meanwhile, Piper Jaffray analyst Edward Tenthoff recommends buying shares of Vertex Pharmaceuticals (VRTX) following yesterday's selloff. Tenthoff believes that drugs like Vertex's Orkambi will maintain premium pricing because of the disease modifying value to patients and payors. Orkambi is approved to treat cystic fibrosis in patients 12 years and older. The analyst reiterates an Overweight rating on Vertex with a $163 price target. DOWNGRADE: Brean Capital analyst Difei Yang downgraded Horizon Pharma (HZNP) to Hold saying "unsettling recent developments" make the stock's premium valuation no longer justified. The public discussion on high drug prices is a negative for the company while its attempt to acquire Depomed (DEPO) is unlikely to result in a completed deal, Yang tells investors in a research note. Further, Horizon's prescription trends are showing weakness, said Yang, who views the stock as more risky than in the past. PRICE ACTION: Horizon closed yesterday down $2.93, or 9.2%, at $28.99, while Vertex dropped $5.97, or 4.8%, to $118.19. A number of the biggest stocks in biotechnology were also weak yesterday, with Gilead sliding about 2.5%, Amgen (AMGN) dropping 2.3%, Celgene declining 2.8% and Biogen (BIIB) falling more than 5.5%.
|07:52 EDT||ATVI||Activision Blizzard price target raised to $36 from $30 at Baird|
Subscribe for More Information
|06:43 EDT||HZNP||Horizon Pharma downgraded to Hold from Buy at Brean Capital|
Brean Capital analyst Difei Yang downgraded Horizon Pharma (HZNP) to Hold saying "unsettling recent developments" make the stock's premium valuation no longer justified. The public discussion on high drug prices is a negative for the company while its attempt to acquire Depomed (DEPO) is unlikely to result in a completed deal, Yang tells investors in a research note. Further, Horizon's prescription trends are showing weakness, the analyst points out. Yang views the stock as more risky than in the past. Horizon closed yesterday down $2.93 to $28.99.
|September 21, 2015|
|13:31 EDT||AMZN||After Emmys, analyst sees 'growing threat' to established content creators|
Netflix (NFLX), Time Warner (TWX), and Viacom (VIA) shares fell in midday trading following last night's Emmy Awards, while Amazon (AMZN) climbed. An analyst called the combined nominations for Netflix and Amazon a an indication that emerging over-the-top streaming services have become a "growing threat to the establishment." WHAT'S NEW: HBO, a Time Warner network, dominated the 67th Annual Emmy Awards, walking away with 43 awards overall, including 29 Creative Emmys, while Netflix won four awards, as did Viacom's Comedy Central. Amazon, meanwhile, achieved its first-ever Emmy wins with five total awards. Following HBO's performance at the annual awards show, Netflix Chief Executive Officer Reed Hastings tweeted: "Congrats @HBO on supporting so much Emmy-winning talent. Your leadership of great television is inspiring." Netflix was nominated for 34 awards, while Amazon was nominated for 12. STREET RESEARCH: Cantor Fitzgerald analyst Youssef Squali said that while Netflix's four Emmys this year was "somewhat disappointing" considering last year's seven, the service's performance at the awards show was "notable," particularly since the company has long been underestimated by bigger and more established content creators. Squali said that the combined 46 nominations for both Netflix and Amazon is a "clear indication" that emerging over-the-top streaming services have become a "growing threat to the establishment" and that it's "a matter of time" before such services begin to rival and possibly exceed their "linear cousins." The analyst sees Netflix gaining strong momentum heading into the second half of fiscal 2015 and 2016 and reiterated a Buy rating on the company's stock with a $125 price target. PRICE ACTION: Netflix shares are down 1.95% to $100.62 in afternoon trading. Meanwhile, Time Warner is down 0.29% to $69.44, Viacom is down 2.42% to $45.58, and Amazon is up 0.94% to $545.32.
|12:55 EDT||AMZN||On The Fly: Top stock stories at midday|
Stocks began the session with a triple digit gain for the Dow and remained in a fairly narrow range for most of the morning. However, once the European markets closed, the U.S. averages weakened and are now struggling to remain in positive ground. ECONOMIC EVENTS: In the U.S., existing home sales fell 4.8% to a 5.31M rate in August, versus expectations for them to be down 1.6% to a rate of 5.5M. Over the weekend, three Federal Reserve officials, namely an Francisco Fed President John Williams, St. Louis Fed President James Bullard and Richmond Fed President Jeffrey Lacker, all argued that an interest-rate increase is still warranted this year. In Europe, Alexis Tsipras' Syriza party gained 35.5% of the vote in the Greek election. COMPANY NEWS: Shares of Volkswagen (VLKAY) trading in Germany plunged and the ADRs trading in New York dropped more than 17.5% after the EPA and California Air Resources Board detected manipulations that violate American environmental standards while testing Volkswagen diesel cars. The EPA said Volkswagen may face civil penalties of $37,500 for each vehicle not in compliance with federal clean air rules, which could total as much as $18B, according to Reuters... Time Warner's (TWX) HBO dominated the Emmy awards ceremony with 43 awards, including the 29 Creative Emmys it won last week. Meanwhile, Amazon (AMZN) earned its first-ever Emmy wins and Netflix (NFLX) CEO Reed Hastings, whose company won four awards, tweeted out: "Congrats @HBO on supporting so much Emmy-winning talent. Your leadership of great television is inspiring." MAJOR MOVERS: Among the notable gainers was Atmel (ATML), which jumped 12% after agreeing to be acquired by German chipmaker Dialog Semiconductor in a deal valued at approximately $4.6B, or the equivalent of $10.42 per Atmel share. Among the noteworthy losers was Mallinckrodt (MNK), which dropped 9% following the announcement that ANI Pharmaceuticals (ANIP) plans to acquire two new drug applications from Merck (MRK) that could compete with Acthar, Mallinckrodt's largest product. Also lower was uniQure (QURE), which fell 15% after announcing topline results of one-year follow-up data from a Phase I/II clinical trial in four Sanfilippo B syndrome patients. Both stocks were among the many big pharma and biotech decliners after Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug that treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. INDEXES: Near midday, the Dow was up 38.57, or 0.24%, to 16,423.15, the Nasdaq was down 21.13, or 0.44%, to 4,806.10, and the S&P 500 was up 1.85, or 0.09%, to 1,959.88.
|11:14 EDT||AMZN||Netflix gaining momentum after last night's Emmy's, says Cantor|
Netflix (NFLX) left last night's 67th Emmy Awards with four trophies and Amazon (AMZN) "a surprising" five, Cantor Fitzgerald analyst Youssef Squali points out in a research note to investors. Netflix's performance is "somewhat disappointing" relative to last year's seven emmys, but it's still a "notable performance" for an $8.99 per month service that started in 2012, Squali argues. The combined 46 nominations for Netflix and Amazon is a "clear indication" that over-the-top streaming services are a "growing threat to the establishment," Squali writes. The analyst views this phenomenon, coupled with solid reviews for Narcos, ongoing expansion throughout Asia and a recent price hike in major European markets as signs Netflix is seeing strong momentum into the second half of 2015. He reiterates a Buy rating on the stock with a $125 price target. Netflix is up 15c to $102.71 in late morning trading.
|09:14 EDT||AMZN||Netflix CEO congratulates HBO on Emmy dominance|
Netflix (NFLX) CEO Reed Hastings tweeted out: "Congrats @HBO on supporting so much Emmy-winning talent. Your leadership of great television is inspiring." Time Warner's (TWX) HBO dominated the Emmy awards ceremony with 43 awards over all, including 29 Creative Emmys last week. Viacom's (VIA) Comedy Central, with four wins, was the network with the second-highest number of awards last night. Meanwhile, Hastings' won Netflix won four awards and Amazon (AMZN) earned its first-ever Emmy wins with two awards for its series "Transparent." Reference Link